Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $598000.0.

  • Protalix BioTherapeutics' Share-based Compensation fell 354.84% to $598000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 4404.94%. This contributed to the annual value of $3.3 million for FY2024, which is 565.55% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Share-based Compensation stood at $598000.0, which was down 354.84% from $427000.0 recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Share-based Compensation high stood at $1.4 million for Q4 2023, and its period low was $288000.0 during Q2 2022.
  • Moreover, its 5-year median value for Share-based Compensation was $578000.0 (2021), whereas its average is $669789.5.
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 6018.39% in 2021, then skyrocketed by 15995.26% in 2023.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Share-based Compensation stood at $418000.0 in 2021, then grew by 28.95% to $539000.0 in 2022, then surged by 153.62% to $1.4 million in 2023, then plummeted by 52.16% to $654000.0 in 2024, then decreased by 8.56% to $598000.0 in 2025.
  • Its Share-based Compensation stands at $598000.0 for Q3 2025, versus $427000.0 for Q2 2025 and $540000.0 for Q1 2025.